Hepatocellular carcinoma: Clinical trials to watch

Area of Science:

• Hepatobiliary medicine
• Oncology
• Translational research

Background:

• Hepatocellular carcinoma (HCC) remains a significant global health challenge.
• Current management strategies for HCC require optimization for improved patient outcomes.
• Advances in screening and treatment offer potential to transform HCC care.

Purpose of the Study:

• To summarize ongoing clinical trials in hepatocellular carcinoma (HCC) screening and treatment.
• To highlight advancements in early detection methods for HCC.
• To review the evolving therapeutic landscape for HCC, including immune checkpoint inhibitors.

Main Methods:

• Review of current and upcoming clinical trials for HCC.
• Comparison of novel screening strategies (imaging, blood-based) against standard ultrasound.
• Analysis of therapeutic trials investigating immune checkpoint inhibitors and new regimens for various HCC stages.

Main Results:

• Novel imaging and blood-based biomarkers are being evaluated for early HCC detection, aiming to outperform abdominal ultrasound.
• Immune checkpoint inhibitors show promise and are being tested in early, intermediate, and advanced stages of HCC.
• New treatment regimens are under investigation to enhance survival rates across the spectrum of HCC.

Conclusions:

• Ongoing trials hold significant potential to revolutionize the management of hepatocellular carcinoma.
• Advancements in screening and immunotherapy are expected to improve early diagnosis and patient survival.
• The therapeutic landscape for HCC is rapidly evolving, offering new hope for patients at all disease stages.